Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP
about
A review of the nonpressor and nonantidiuretic actions of the hormone vasopressinCurrent controversies in the diagnosis and management of von Willebrand diseaseTransient mild hyperthermia induces E-selectin mediated localization of mesoporous silicon vectors in solid tumorsCav3.1 (alpha1G) controls von Willebrand factor secretion in rat pulmonary microvascular endothelial cells.Von Willebrand disease: an overviewRegulation of cellular communication by signaling microdomains in the blood vessel wall.New aspects in the pathogenesis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.Pathophysiology of copeptin in kidney disease and hypertensionIn vivo imaging analysis of the interaction between unusually large von Willebrand factor multimers and platelets on the surface of vascular wall.The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF.Functional architecture of Weibel-Palade bodies.Recurrent myocardial infarctions in a young football player secondary to thrombophilia, associated with elevated factor VIII activity.Extracellular cAMP inhibits proximal reabsorption: are plasma membrane cAMP receptors involved?Von Willebrand factor and von Willebrand disease.A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand diseaseSphingosine-1-phosphate receptor 3 mediates sphingosine-1-phosphate induced release of weibel-palade bodies from endothelial cells.Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats.Copeptin is an independent predictor of diabetic heart disease and death.Regulatory components of the alternative complement pathway in endothelial cell cytoplasm, factor H and factor I, are not packaged in Weibel-Palade bodies.The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.Neonatal DNA methylation patterns associate with gestational age.Treatment of patients with von Willebrand disease.Factor VIII Is Synthesized in Human Endothelial Cells, Packaged in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings.Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storageIn vivo gene transfer strategies to achieve partial correction of von Willebrand disease.Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model.A Selective V(1A) Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic ShockThe vessel wall and its interactions.Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosisReduction of tumor angiogenesis induced by desmopressin in a breast cancer modelArginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).Acquired hemophilia: a rare but life-threatening potential cause of bleeding in the intensive care unit.Bleeding in the patient with a malignancy: is it an acquired factor VIII inhibitor?Hyponatremia: an update on current pharmacotherapy.Diabetes insipidus: a challenging diagnosis with new drug therapiesG protein-coupled receptor kinase 2 moderates recruitment of THP-1 cells to the endothelium by limiting histamine-invoked Weibel-Palade body exocytosis.Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system.Platelet sequestration and activation during GalTKO.hCD46 pig lung perfusion by human blood is primarily mediated by GPIb, GPIIb/IIIa, and von Willebrand Factor.Acute pulmonary thromboembolism occurring during treatment with tolvaptan in a patient with autosomal-dominant polycystic kidney disease.
P2860
Q21131156-ACC28C38-334E-4822-97E7-299CC3C9942AQ26796446-A4848484-FD18-4712-A7B8-7CECA65D8396Q27330421-E508DEB1-4880-4D77-9E6C-9F77E19882FBQ28575971-9064F37C-3B6D-400A-8AED-D8CB456E335DQ28742241-185ACA94-ADC2-4B90-8C2A-338C4AFD8457Q30406156-39F4F408-D59D-4763-B7EE-22FF1721EE72Q33339749-B0997681-CD6D-45A1-B40E-28F83A24B723Q33792317-1847E53E-C7AC-41F0-A762-D50EE9933B36Q33873826-E5E74A3B-85C9-4F11-BA34-F988C71543F1Q33896726-BB138782-86F4-4979-AA63-ECE2FCA19B97Q34160799-77D5B129-5F5F-433E-821D-4217E34CBCADQ34464688-520B9891-EAAB-4F1A-905E-1A37514B1102Q34520624-2206AAF7-45D9-43CC-9D0F-AC539540A9FBQ34530389-D69AB99F-6D09-41EC-9ABF-060D78A753F5Q34909055-18104911-9C49-42B8-8A8B-AF10A1BD8BE2Q35121901-244FBB0F-5841-4723-BF22-3B52ADF1853AQ35228123-EF8D62DD-72A5-48BE-8FB6-1B3E33497A97Q35433105-F48EFA90-73E4-42A8-A50F-B1D59B8F110FQ35585484-3162721E-7D74-4D95-9BCB-00032BF219A8Q35636438-6F4AC5B0-C86E-4DE1-A018-533C8E6F6232Q35667395-C35B09E9-EE10-4C7C-9D53-C214A3BB5CD4Q35683876-00263DE5-F4D3-4587-A8F7-6DFA35F576A9Q35810108-83C6B584-F5D6-41CA-8D30-72F828BD9567Q35848737-D1CEBB42-830D-481F-A893-825AACAA7837Q35995241-CA390374-E706-4A08-AC43-493A4E248B53Q36084450-702D214F-D7B7-4A70-889F-DC5750EB4F07Q36174498-D1D04AB7-B815-4D41-938F-4D4082EB244CQ36384718-E498410C-3DDC-42F1-8422-2B2BDAE8352BQ36677300-AF05BD20-C302-45C5-B800-3CACE796BE35Q37250071-F923613C-303F-46F2-B56F-D6E2F2C41F96Q37302108-356E7AAD-89C9-459E-9876-3E42E4E4CCC7Q37843827-636B55D3-8FAA-49A8-8188-6AF0E5BD71A8Q37882559-3C4E01CE-6128-4F6B-AAF0-FFFABE634125Q37896539-CC3207E6-B210-4E21-9367-2540A27D7167Q38089919-3128661E-2DE6-40A1-ABD8-A29FAA40C6BFQ38224495-1898E664-6DBA-4E05-93C1-516F8190BD11Q38307746-BBBF231D-480F-4B4E-A5A0-9EA23E6586B6Q38695316-210640A3-95A9-429A-BC96-EAFA145635FAQ41339114-2BD2A6FC-8BAC-4BB3-95AF-369DB529ED07Q41855559-8B6EBEA8-231B-4D43-AFA2-1F7491E9CB4D
P2860
Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@ast
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@en
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@en-gb
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@nl
type
label
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@ast
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@en
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@en-gb
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@nl
prefLabel
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@ast
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@en
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@en-gb
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@nl
P2093
P2860
P921
P356
P1476
Vasopressin-induced von Willeb ...... involves V2 receptors and cAMP
@en
P2093
C B Wollheim
J E Kaufmann
U M Vischer
W Rosenthal
P2860
P304
P356
10.1172/JCI9516
P407
P577
2000-07-01T00:00:00Z